We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed at $210.26 in the latest trading session, marking a +1.84% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 1.18%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated Nasdaq saw an increase of 1.96%.
Prior to today's trading, shares of the drugmaker had lost 6.76% lagged the Medical sector's loss of 1.56% and the S&P 500's gain of 3.93%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company is slated to reveal its earnings on April 29, 2026. The company's earnings per share (EPS) are projected to be $2.89, reflecting a 17.48% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $14.78 billion, indicating a 10.75% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $14.4 per share and revenue of $66.98 billion, which would represent changes of +44% and +9.51%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.09% lower. Currently, AbbVie is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is currently trading at a Forward P/E ratio of 14.34. For comparison, its industry has an average Forward P/E of 14.34, which means AbbVie is trading at no noticeable deviation to the group.
Investors should also note that ABBV has a PEG ratio of 0.73 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.32 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 168, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
AbbVie (ABBV - Free Report) closed at $210.26 in the latest trading session, marking a +1.84% move from the prior day. The stock outperformed the S&P 500, which registered a daily gain of 1.18%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated Nasdaq saw an increase of 1.96%.
Prior to today's trading, shares of the drugmaker had lost 6.76% lagged the Medical sector's loss of 1.56% and the S&P 500's gain of 3.93%.
The investment community will be paying close attention to the earnings performance of AbbVie in its upcoming release. The company is slated to reveal its earnings on April 29, 2026. The company's earnings per share (EPS) are projected to be $2.89, reflecting a 17.48% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $14.78 billion, indicating a 10.75% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $14.4 per share and revenue of $66.98 billion, which would represent changes of +44% and +9.51%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for AbbVie. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.09% lower. Currently, AbbVie is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, AbbVie is currently trading at a Forward P/E ratio of 14.34. For comparison, its industry has an average Forward P/E of 14.34, which means AbbVie is trading at no noticeable deviation to the group.
Investors should also note that ABBV has a PEG ratio of 0.73 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.32 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 168, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.